The eukaryotic translation initiation factor eIF4E is a potent oncogene elevated in many cancers, including the M4 and M5 subtypes of acute myeloid leukemia (AML). Although eIF4E RNA levels are elevated 3-to 10-fold in M4/M5 AML, the molecular underpinnings of this dysregulation were unknown. Here, we demonstrate that EIF4E is a direct transcriptional target of nuclear factor kappa-lightchain-enhancer of activated B cells (NF-kB) that is dysregulated preferentially in M4 and M5 AML. In primary hematopoietic cells and in cell lines, eIF4E levels are induced by NF-kB activating stimuli. Pharmacological or genetic inhibition of NF-kB represses this activation. The endogenous human EIF4E promoter recruits p65 and cRel to evolutionarily conserved kB sites in vitro and in vivo following NF-kB activation. Transcriptional activation is demonstrated by recruitment of p300 to the kB sites and phosphorylated Pol II to the coding region. In primary AML specimens, generally we observe that substantially more NF-kB complexes associate with eIF4E promoter elements in M4 and M5 AML specimens examined than in other subtypes or unstimulated normal primary hematopoietic cells. Consistently, genetic inhibition of NF-kB abrogates eIF4E RNA levels in this same population. These findings provide novel insights into the transcriptional control of eIF4E and a novel molecular basis for its dysregulation in at least a subset of M4/M5 AML specimens.
INTRODUCTION
The eukaryotic translation initiation factor 4E (EIF4E) is a potent oncogene that is inappropriately elevated in about 30% of human cancers, including the M4 and M5 subtypes of acute myeloid leukemia (AML) and in blast crisis, but not in chronic phase, CML.
1 eIF4E overexpression leads to increased proliferation, evasion of apoptosis, oncogenic transformation, tumor invasion and metastases. [1] [2] [3] [4] [5] eIF4E interacts with the methyl-7-guanosine cap moiety on the 5 0 end of mRNAs 6 and via this activity has a central role in cap-dependent translation and in nucleo-cytoplasmic export of a subset of transcripts encoding proteins involved in cellular growth, survival and transformation such as Cyclin D1, VEGF, c-myc, Mcl1 and Pim1. 7, 8 Both the translation and export activities of eIF4E contribute to its transformation potential. 9 Depletion of eIF4E in cancer cells using small interfering RNA, anti-sense oligonucleotides or pharmacological inhibitors leads to cell cycle arrest and decreased tumorigenicity. [10] [11] [12] [13] Targeting of eIF4E with a competitive inhibitor of the m 7 G cap moiety, ribavirin, led to clinical responses in poor prognosis of M4 and M5 AML patients, including remissions in a phase II trial. 10 Few studies have focused on how eIF4E RNA levels become elevated in malignant cells. In M4 and M5 AML specimens, eIF4E RNA and protein levels are elevated by B3-to 10-fold relative to primary hematopoietic cells from healthy volunteers. 10 Traditionally, transcription of EIF4E was thought to be controlled only by c-Myc. 14 Other studies have implicated Sonic hedgehog signaling 15 and p53 16 in the control of EIF4E transcription, but these too are ultimately considered to be mediated by c-Myc interaction with the EIF4E promoter. Interestingly, eIF4E expression is still stimulated in response to serum in Myc null fibroblasts indicating that there are other mechanisms to control EIF4E transcription. 17 Consistent with this idea, a recent report suggests that EIF4E is also a C/EBP target. 18 Our previous studies in primary M4 and M5 AML specimens suggested a tantalizing link between NF-kB and the transcription of EIF4E. Introduction of the NF-kB inhibitor, IkB-super repressor (IkB-SR) into primary M4 or M5 AML specimens, which are characterized by constitutive NF-kB activity, resulted in a substantial reduction in eIF4E transcript and protein levels. 19 However, to date, whether the link between NF-kB and eIF4E was a direct one, had not been investigated.
The NF-kB family of transcription factors has a central role in the regulation of growth, proliferation, inflammation and apoptosis.
the IKK-kinase complex, which phosphorylates the IkB molecules leading to their proteasomal degradation. Free NF-kB dimers translocate into the nucleus, where they bind cognate DNA sequences known as kB sites (consensus 5 0 -GGGRNYYYCC-3 0 ) via their Rel homology domain to regulate gene transcription. 22, 23 Importantly, introduction of a dominant negative repressor of NFkB and IkB-SR, which blocks its nuclear translocation leads to reduced growth of primary AML cells. 19 In this study, we establish that eIF4E is a direct transcriptional target of NF-kB in hematopoietic cell lines and primary normal hematopoietic cells. Further, studies in primary M4/M5 AML specimens indicate that at least for the specimens examined the eIF4E promoter elements are preferentially occupied relative to M1 and M2 AML subtypes with normal eIF4E levels or to healthy, unstimulated, hematopoietic cells. These studies suggest that NF-kB activation can differentially target subsets of genes in specific AML contexts. These findings provide a novel control mechanism for eIF4E expression and a novel basis for its dysregulation in AML, and likely in other malignancies characterized by activated NF-kB.
MATERIALS AND METHODS

Primary cell isolation and treatments
Primary B cells were purchased from Stem Cell Research. Primary AML samples from anonymous patients (M1, M2, M4 and M5) were obtained from the BCLQ (Banque de Cellules Leucémiques du Québec) with ethics committee approval from the University of Montreal (Comité d'éthique de la recherche en santé CEFRM no. 195). Leukaphereses from healthy donors were obtained at the Royal Victoria Hospital, Montreal, Quebec, Canada with ethics committee approval from the Jewish General Hospital and McGill University Research Ethics Committee board of the SMBD-Jewish General Hospital (protocol number no. 06-103). Written informed consent was obtained from both healthy donors and AML patients in accordance with the Declaration of Helsinki. Characteristics of the AML primary specimens used in this study are presented in Supplementary  Table 1 . AML cells were thawed in RPMI 1640 (Invitrogen, Life Technologies, Burlington, ON, Canada) supplemented with 10% heat inactivated fetal bovine serum and 100 U of penicillin/streptomycin (Invitrogen). Nuclear lysates were prepared from 4 million cells, respectively.
Peripheral blood mononuclear cells were isolated with Ficoll-Paque PLUS (Invitrogen) according to the manufacturer's instructions. Cells were resuspended in RPMI 1640 (Invitrogen) supplemented with 15% heat inactivated fetal bovine serum and 100 U of penicillin/streptomycin (Invitrogen). Cells were plated at a density of 30 Â 10 6 cells in T75 flasks and treated with PMA (Phorbol 12-myristate 13-acetate, Sigma, Oakville, ON, Canada) at 20 ng/ml for the described time points. For NF-kB inhibition, cells were pretreated for 1 h with 10 mM Bay 11-7082 (Sigma) before PMA stimulation and the inhibitor was kept in the media throughout the experiment.
Cell culture BJAB (Burkitt's cell lymphoma), KG1a (M0 AML) and THP1 (M5 AML) cells were obtained from and cultured according to the American Type Culture Collection (ATCC). KM-H2 (Hodgkin's) lymphoma cell line was a kind gift from Dr Sigrun Smola. The BJAB cell line used was always cultured at low density, maintained at B70% confluency and kept from reaching full confluency. BJAB cells (10 6 cells in six-well plates) were treated with 20 ng/ml PMA (Sigma). NF-kB inhibition was carried out using the Bay 11-7082 (Sigma) by pretreating the cells with 10 mM for 1 h before stimulation with PMA.
Antibodies and primers
The following antibodies were used: p50 (Rockland Immunochemicals, 100-4164; Cedarlane Laboratories, Burlington, ON, Canada), Rel A (p65) (Rockland Immunochemicals, 100-4165), cRel (Cell Signaling no. 4727S, New England Biolabs, Whitby, ON, Canada), p300 (Rockland Immunochemicals, 100-301-76), eIF4E (BD Transduction laboratory, 610270, Mississauga, ON, Canada), S2/5 phospho-RNA polymerase II (Cell Signaling no. 4735S) and b-actin (Sigma, A5441). Specific primers designed for gel shift assays, chromatin immunoprecipitation (ChIP) and expression analysis are summarized in Supplementary 
Expression analysis
Total RNA was isolated from control and treated cells using Trizol (Invitrogen) according to the manufacturer's instructions. RNA was additionally treated with RNase-free DNase I (Ambion, Life Technologies). Complementary DNA was synthesized using M-MLV Reverse Transcriptase (Invitrogen) and expression analysis was then performed with quantitative real-time PCR using the StepONE real-time PCR (Applied Biosystems, Life Technologies). C t values were analyzed using the DDCT method 25 and normalized to b-Actin, Histone 2B and Ubiquitin. Total protein was extracted with RIPA buffer (Tris 50 mM, NaCl 150 mM, SDS 0.1%, sodium deoxycholate 0.5% and NP-40 1%) and analyzed by western blot using chemiluminescence (Thermoscientific, Fisher, Ottawa, ON, Canada). Western blot band densities were analyzed with ImageJ software (ImageJ, US National Institutes of Health, Bethesda, MD, USA).
RESULTS
NF-kB activation stimulates eIF4E expression in hematopoietic cell lines Our previous studies indicated that eIF4E is highly elevated (B3-to 10-fold) in M4/M5 AML specimens but generally not in other AML subtypes or in a variety of primary hematopoietic cells isolated from healthy volunteers, including CD34 þ cells, granulocytes and monocytes. 10, 19, 26 Given our previous finding that IkB-SR expression in a primary M5 AML specimen repressed eIF4E RNA levels, we investigated the potential role of NF-kB activity in the direct transcriptional control of eIF4E. In M4/M5 AML cells, NF-kB activity is constitutive thus, we used a hematopoietic cell line BJAB as a model system because of its low-basal NF-kB activity, which enabled us to examine the effects of NF-kB activation. 22, 23, 27 Cells treated with PMA, an NF-kB stimulator, exhibited a rapid increase in eIF4E mRNA, with levels doubling at 3 h (Figure 1a) , as determined by quantitative real-time PCR and a parallel increase in eIF4E protein levels up to sevenfold was also observed (Figure 1d ). Known NF-kB targets, MYC and CCND1, also displayed a similar increase (two-to threefold) upon PMA stimulation of these cells (Figures 1b and c) . Given that PMA is a pleiotropic agent, we assessed the effects of the pharmacological-IKK complex inhibitor Bay 11-7082, 28 which blocks IkBa phosphorylation. The observed induction of eIF4E mRNA expression was completely abrogated when samples were treated with Bay 11-7082, consistent with the hypothesis that the increase in eIF4E mRNA observed is due to NF-kB activation ( Figure 1a ).
The NF-kB subunits cRel and p65 directly alter EIF4E promoter activity We analyzed the human EIF4E promoter (up to 863 bp upstream of the transcriptional start site) using bioinformatics (MatInspector 24 ) for the presence of kB sites. Previous analysis of the rat EIF4E promoter had suggested the presence of two putative Rel elements but these were never examined for activity. 29 We identified four kB sites (denoted kB1 through 4 in the text) centered on positions À 836, À 808, À 630 and À 348 relative to the transcriptional start site (Figure 2a and Supplementary  Figure 2A ). These sites are evolutionary conserved in human, cow, monkey, mouse and rat (Supplementary Figure 2B) . Note that the NF-kB pathway is absent in yeast and worms 20 although both express eIF4E suggesting an evolutionary emergence of an NF-kBeIF4E is a direct transcriptional target of NF-kB F Hariri et al mediated mechanism to induce eIF4E expression in higher organisms. Our analysis also revealed the presence of binding sites for several other transcription factors (PU.1, Pax5, Octamer, NF-AT) (not shown). Although the significance of these novel binding sites needs further investigation, they are suggestive of a more intricate transcriptional control of eIF4E than the prevailing model of transcriptional regulation solely through Myc. In order to determine whether activating signals induce binding of NF-kB complexes to the putative kB elements in the EIF4E promoter, we carried out EMSA using nuclear extracts from BJAB cells in the presence and absence of PMA. These cells exhibited low basal levels of NF-kB activity, which could be dramatically induced by PMA treatment as determined by EMSA using the kappa light chain consensus motif (Figure 2b ). At 90 min poststimulation, all four of the predicted kB elements yielded inducible complexes when incubated with nuclear extracts (Figure 2c and Supplementary Figure 3) . The complexes were specific, as they could be competed by excess cold probe corresponding to the consensus kappa light chain kB motif 30 ( Figure 2c , lane 6), but not with a cold probe corresponding to mutant sites for kB3 and kB4 (Figure 2d ). Supershift analysis with antibodies against p50, p65 and cRel revealed cRel/p65 heterodimers bound to the promoter elements ( Figure 2c, lanes 2 and 4) . Although some p50 protein was supershifted (Figure 2c, lane 3) , specific bands corresponding to p50-containing complexes could not be detected, suggesting that p50 is not a central component of the bound complexes. These experiments demonstrated that all four kB sites in the EIF4E promoter recruit cRel/p65 complexes.
NF-kB recruits p300 and Pol II to the EIF4E promoter in vivo To establish that the NF-kB complexes detected by EMSA formed not only in vitro on eIF4E promoter fragments but also in cells, we carried out ChIPexperiments in BJAB cells treated with PMA for 1 or 2 h (Figure 3 ). Our results revealed maximum cRel binding at 1 h post-treatment, with threefold enrichment at the kB3 site and a twofold enrichment at the kB4 site (Figure 3b ). The p65 subunit was recruited to both sites following 1 h of treatment with maximal ninefold and 10-fold enrichment at the kB3 and kB4 sites, respectively (Figure 3a) . Activated NF-kB (cRel and p65) dimers bound to the EIF4E promoter effectively recruited p300 histone acetyl transferase, a marker of transcriptionally active NF-kB complexes. 31 Maximum p300 enrichment was again observed 1-h post-treatment: ninefold for kB3 and sevenfold for kB4 (Figure 3c ). In contrast, no binding of NF-kB subunits was detected at the kB1 and kB2 sites by real-time PCR at 1 or 2 h post-PMA treatment (data not shown). This suggests that the kB1 and kB2 sites are not active in vivo in this context, possibly due to the chromatin status at the eIF4E locus. Phosphorylated Pol II was significantly enriched at the EIF4E coding region with twofold at 1 h and fivefold at 2 h (Figure 3d ) confirming enhanced EIF4E gene transcription. Thus, shortly after NF-kB stimulation, binding of cRel/p65 dimers at the kB3 and kB4 but not kB1 and kB2 sites of the EIF4E promoter results in transcriptional upregulation of eIF4E expression via recruitment of p300.
NF-kB activation induces eIF4E transcription in primary human cells To examine the biological relevance of our findings to the normal control of EIF4E transcription, we assessed eIF4E levels as a function of PMA stimulation in primary peripheral blood mononuclear cells isolated from two healthy individuals (Figure 4,  Supplementary Figure 1) . PMA-induced eIF4E mRNA expression as early as 2 h with maximal induction at 4 h (fourfold upregulation relative to the untreated controls, Figure 4a ). Increased eIF4E mRNA levels were observed up to 12 h post-treatment (threefold). Figures 1A and B) . Results were similar for eIF4E from another healthy volunteer (Figure 4b ). Flow cytometry analysis of the same samples revealed a significant increase in the population of cells with elevated eIF4E protein levels ( Supplementary Figures 1C and  D) . Upon treatment with the NF-kB inhibitor, Bay 11-7082, we observe that both eIF4E mRNA and protein expression were no longer induced by PMA, consistent with these effects being mediated through NF-kB. Furthermore, eIF4E mRNA was monitored as a function of PMA stimulation in primary B lymphocytes as a direct primary companion to BJABs. eIF4E transcript doubled at 2 h and reached a maximum of fourfold at 6 h in an NF-kB dependent manner (Figures 4c and d) . Thus, eIF4E is an NF-kB inducible gene in primary hematopoietic cells.
eIF4E transcription is elevated in cells with constitutively active NF-kB Many cancers, including AML are characterized by constitutively active NF-kB. 21 Thus, we monitored eIF4E in KM-H2 cells, which are hematopoietic cells characterized by constitutively active NFkB, owing to a somatic mutation in the IkBa gene. 32 In these cells, EMSA analysis revealed constitutive binding of NF-kB to the kB3 and kB4 sites of the EIF4E promoter (Figure 5a ). Supershift analysis demonstrated the presence of cRel/cRel homodimers as well as cRel/p65 heterodimers; some p65/p50 complexes were also detected with kB4, although their unusually slow migration pattern was suggestive of the presence of an additional unidentified factor(s). To further demonstrate the direct role of NF-kB in this system, we transduced KM-H2 cells with a retroviral vector expressing IkB-SR to block NF-kB activity. Consistently, IkB-SR reduced eIF4E transcript and protein levels as well as those for the c-Myc control (Figures 5b and c) . Thus, eIF4E transcription is elevated in the context of constitutively active NF-kB.
Elevated NF-kB activity in M4 and M5 AML specimens underlies, at least in part, eIF4E dysregulation To determine whether NF-kB transcriptional activity could underlie elevation of eIF4E in primary M4 and M5 AML, we examined NF-kB activity in the AML-M5 cell line, THP1, 33 characterized by elevated eIF4E. 26 Consistent with previous findings, 34 THP1 cells harbor constitutively active NF-kB. Nuclear lysates prepared from THP1 cells exhibited NF-kB specific binding for the four identified promoter elements (Figure 6a ). ChIP analysis performed on these cells revealed Rel A enrichment on all NF-kB elements in the eIF4E promoter as seen in Figure 6b but not to a random region in exon 2 of eIF4E. Note that given the proximity of the kB1 and kB2 elements, the ChIP experiment cannot differentiate between these two sites and thus is referred to as kB1/kB2. Thus, NF-kB is constitutively found on the eIF4E promoter.
Further, we examined NF-kB activity in KG1a cells, a variant AML M0 cell line derived from the AML M1 cell line KG1. 35 KG1a cells are characterized by highly elevated eIF4E that is mainly nuclear (Supplementary Figures 4A and B) . Similar to THP1, nuclear lysates from KG1a cells demonstrated NF-kB binding for all four identified promoter elements (Supplementary Figure 4c) and ChIP analysis indicated Rel A enrichment for all the elements (Figure 6b) . Thus, elevation of eIF4E by NF-kB activity is not necessarily lineage restricted and could also explain how eIF4E levels become elevated in a fraction of other AML subtypes characterized by elevated eIF4E.
To assess whether our findings could be translated to patient specimens, we extended our studies to primary AML specimens. We observed no substantial differences in constitutive NF-kB activity across AML subtypes as determined by EMSA experiments using the consensus kappa light chain element consistent with previous reports 21 ( Figure 7a ). To assess if the EIF4E promoter was specifically enriched for NF-kB proteins we carried out EMSA experiments with all four promoter elements in these AML specimens. We observed complexes highly enriched on the kB3 promoter elements in M4 and M5 specimens (in 2/2 M4 and 2/2 M5) relative to the M1 and M2 specimens (0/1 M1 and 0/2 M2 specimens), which were previously characterized by normal eIF4E levels 26 ( Figure 7a and Supplementary Table 1) . Consistently, the N E C C P + A n ti-cR e l + A n ti-p 6 5 N E C C P + A n ti-cR e l + A n ti-p 6 5 N E C C P + A n ti-cR e l + A n ti-p 6 5 N E C C P + A n ti-cR e l + A n ti-p 6 5 eIF4E is a direct transcriptional target of NF-kB F Hariri et al kB4 element was preferentially occupied in M4 and M5 specimens relative to the M1 and M2 specimens (Figure 7a ). Further, we observed supershifts using antibodies to Rel A and cRel consistent with these being NF-kB complexes with predominant Rel A species (Figure 7b) . Additionally, M4/M5 nuclear lysates strongly bound the kB1 and kB2 elements (Figure 7c ). This is consistent with our previous findings that eIF4E RNA and protein levels are preferentially elevated in M4 and M5 relative to M1 and M2 AML subtypes with B44/44 M4/M5 AML specimens and 2/22 M1/M2 AML specimens relative to five healthy controls. 1, 10, 19, 26 To assess the functional relevance of these associations, we used ChIP analysis performed to monitor Rel A recruitment in the examined AML samples. Rel A was recruited to kB1/kB2 and kB3 but not kB4 in the M4/M5 samples but not the M2 (Figure 7d ). Although all four elements were bound by nuclear lysates from PMA-induced BJABs as well as the NF-kB constitutive AML cell line (THP1) and primary specimens through EMSA assays, ChIP assays revealed Rel A recruitment to the kB1/kB2 elements in only the AML primary specimens and cell line but not in BJAB cells implying a lineage-specific recognition for NF-kB proteins on the eIF4E promoter. Importantly, kB3 elements were also bound in the ChIP assays indicating these likely have important roles as well.
Thus, eIF4E promoter elements specifically recruit NF-kB complexes enabling increased EIF4E transcription relative to other AML subtypes. Consistently, previous studies showed that introduction of IkB-SR into primary M4 and M5 AML specimens resulted in reduced eIF4E mRNA and protein levels. 19 It seems likely that NF-kB dysregulation in at least a subset of M4/M5 AML underlies, at least in part, aberrant elevation of eIF4E RNA levels in the evaluated samples. Clearly, more specimens will need to be examined to determine the generality of these findings.
DISCUSSION
This study reveals novel insights into the control of EIF4E transcription in primary hematopoietic cells, as well as its dysregulation in AML specimens. These are the first studies to show that EIF4E is a transcriptional target of NF-kB. Recently, C/EBP has also been shown to regulate EIF4E transcription 18 and thus NF-kB and C/EBP serve as examples that the transcriptional N E + A n ti-cR e l + A n ti-p 6 5 C C P N E C C P + A n ti-cR e l + A n ti-p 6 5 M4 κB3 κB4
N E C C P + A n ti-cR e l + A n ti-p 6 5 M4 N E C C P + A n ti-cR e l + A n ti-p 6 Figure 7 . Selective NF-kB recognition of the EIF4E promoter elements in M4/M5 AML. EMSA of nuclear extracts prepared from unstimulated PBMCs from a healthy volunteer (Norm) and different M1, M2, M4 and M5 AML primary specimen (corresponding to UPN samples 1-4 as presented in Supplementary Table 1 ) incubated with consensus kB motif or with the kB3 and kB4 elements (a). (b) Supershift analysis (kB3/ kB4) (arrowheads) using antibodies against p65 and cRel as well as competition with consensus cold probe (CCP) are indicated. The asterisk (*) indicates a break in the gel during drying. (c) EMSA of nuclear extracts prepared from M2, M4 and M5 AML primary specimen incubated with kB1/kB2 elements. Supershift analysis (arrowheads) using antibodies against p65 and cRel as well as competition with consensus cold probe (CCP) are indicated for the M5 AML sample. Free probe is also shown. (d) Chromatin immunoprecipitation was carried out with Rel A antibody using chromatin from the different specimen (Norm, M2, M4 and M5) used in (a). Recruitment to the kB elements was monitored by quantitativePCR. Data were normalized to the IgG control and depicted as fold enrichment with respect to the normal healthy specimen (Norm). Error bars represent s.d. from triplicate measurements.
eIF4E is a direct transcriptional target of NF-kB F Hariri et al control of eIF4E, thought for nearly 16 years to be solely the purview of c-Myc, is more complicated. These findings suggest that there could be eventual clinical utility in controlling the transcription of EIF4E with the use of NF-kB inhibitors, in addition to directly inhibiting eIF4E activity with ribavirin. 10, 12, 26, 36, 37 Interestingly, many NF-kB target genes are in fact eIF4E mRNA export and/or translation targets (for example Myc and cyclin D1) suggesting these pathways cooperate to drive proliferative gene expression. Our results have shown that genetic and pharmacological inhibition of NF-kB result in downregulation of eIF4E targets suggesting that there is a nexus between transcriptional and post-transcriptional gene expression networks to modulate cell proliferation.
Beyond the control of eIF4E, our findings strongly suggest that NF-kB activity is likely heterogeneous amongst AML specimens with regard to other targeted promoters. In other words, the NF-kB-dependent transcription of factors besides eIF4E may be differentially regulated between AML subtypes, potentially contributing to differences in leukemogenic potential. In this way, the kappa light chain occupancy may not be altered amongst subtypes as it is dependent on Rel components, but differences in the sequences of other promoters may lead to increased dependency of these promoters on non-Rel components for transcriptional activation. Furthermore, the selective in vivo recruitment of Rel A to the kB1/2 region in the M4/M5 AML specimens, as well as the M5 AML THP1 cell line but not in the lymphocytic BJAB cells could be due to lineage differences. However, this is not strictly lineage restricted as ChIP studies indicate that in the high eIF4E AML cell line KG1a, enrichment on the kB1/2 binding elements is also observed. These differences could underlie the constitutive eIF4E upregulation in M4/M5 AML and suggest that non-Rel components have a role in this process. Finally, we did not have access to sufficient primary M3 AML (APL) specimens to examine NF-kB activity and thus cannot exclude that this is relevant to this leukemia subtype. However, primary APL specimens and NB4 cells are characterized by normal eIF4E levels and localization suggesting this may not be critical. 19, 38 Thus, specific non-Rel transcriptional cofactors of NF-kB may be specifically dysregulated in M4 and M5 AML, allowing preferential dysregulation of eIF4E, and potentially other promoters. These factors may be involved in the selective NF-kB recruitment to the eIF4E promoter. Examples of non-Rel proteins shown to selectively modulate DNA recognition and transactivation of NF-kB proteins in other contexts include: RPS3, CD40, BAFFR, Akirins, CHFR, PKAIP, AEG-1, ING-4 and others (reviewed in 39 ). Future studies should reveal the identity of non-Rel cofactors, which likely preferentially drive transcription of eIF4E in M4 and M5 AML. In addition to its role in the control of eIF4E expression as outlined here, NF-kB can also regulate eIF4E activity indirectly by modulating its subcellular localization and thus affecting eIF4E levels and activity. 19 In summary, we observe in normal primary hematopoietic cells and in cell lines with normal NF-kB activity, that EIF4E transcription is stimulated by NF-kB activation. We demonstrate that EIF4E is a direct transcriptional target of NF-kB. We observe that in the M4 and M5 AML specimens examined, the eIF4E promoter is highly occupied by NF-kB complexes. These studies elucidate a novel mechanism of transcriptional control for EIF4E and thus potentially a new point at which to target it.
